The recent cavalcade of biotech deals continued Friday morning, when Bristol Myers Squibb said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines. Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year. The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.
Continue Reading
View Comments
Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.
Published 1 month ago
Oct 10, 2025 at 4:19 PM
Neutral
Auto